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The  genetic  predispositions  which  describe  a diagnosis  of  familial  Alzheimer’s  disease  can  be considered
as  cornerstones  of  the  amyloid  cascade  hypothesis.  Essentially  they  place  the  expression  and metabolism
of  the  amyloid  precursor  protein  as  the main  tenet  of  disease  aetiology.  However,  we  do  not  know  the
cause  of  Alzheimer’s  disease  and  environmental  factors  may  yet  be shown  to contribute  towards  its
onset  and  progression.  One  such  environmental  factor  is human  exposure  to aluminium  and  aluminium
has  been  shown  to be present  in brain  tissue  in sporadic  Alzheimer’s  disease.  We  have  made  the ﬁrst
ever  measurements  of  aluminium  in  brain  tissue  from  12  donors  diagnosed  with  familial  Alzheimer’s
disease.  The  concentrations  of aluminium  were extremely  high,  for example,  there  were  values  in excess
of 10  g/g tissue  dry  wt. in 5 of the 12 individuals.  Overall,  the  concentrations  were  higher  than  allluminium-selective ﬂuorescence
icroscopy
previous  measurements  of  brain  aluminium  except  cases  of known  aluminium-induced  encephalopathy.
We  have  supported  our  quantitative  analyses  using  a  novel  method  of  aluminium-selective  ﬂuorescence
microscopy  to visualise  aluminium  in all lobes  of  every  brain  investigated.  The  unique  quantitative  data
and  the  stunning  images  of  aluminium  in  familial  Alzheimer’s  disease  brain  tissue raise  the  spectre  of
aluminium’s  role  in  this  devastating  disease.
©  2016  The  Authors.  Published  by  Elsevier  GmbH.  This  is  an  open  access  article  under  the  CC. Introduction
Genetic mutations associated with both the expression [1] and
etabolism [2] of amyloid precursor protein (APP) are, in general,
he basis for a diagnosis of familial Alzheimer’s disease (fAD). They,
long with evidence from Down’s syndrome [3], provide strong
upport for the amyloid cascade hypothesis [4,5] and a central role
or the neuropathology and biochemistry of amyloid-beta (A)  in
lzheimer’s disease [6]. In many ways, familial AD has been used
s a blueprint for understanding and treatment of sporadic or late-
nset AD.
Aluminium is present in human brain tissue [7] and in a recent
tudy involving 60 human brains the median aluminium content
f 712 tissues across all four main lobes was 1.02 g/g dry wt.  with
5% of all values being <2.01 g/g dry wt. tissue [8]. The associa-
ion of aluminium and AD has a signiﬁcant history [9,10] and yet
here remains no consensus as to a role for this known neurotoxin
n the disease [11]. However, recent reports concerning sporadic
D [12] and environmental [13] and occupational [14] exposure to
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aluminium have allowed the conclusion to be drawn that, under
certain conditions, it is inevitable that aluminium will contribute
towards AD [11,15]. The suggestion is made that wherever in the
brain the concentration of aluminium is pathologically-concerning
(>2.00 g/g dry wt.) that this aluminium will contribute towards
any ongoing AD and will result in the disease being earlier in onset
with a more aggressive aetiology [15].
Familial AD is characterised by an earlier age of onset and yet
there are no data to describe the aluminium content of brain tissue
in this ‘signature’ form of AD. Herein we have obtained brain tissue
from 12 autopsy-conﬁrmed cases of familial AD and we have car-
ried out the ﬁrst ever measurements of brain aluminium content
in familial AD. We have also supported our quantitative measure-
ments with imaging of brain aluminium by aluminium-selective
ﬂuorescence microscopy.
2. Materials and methods
There was  ethical approval from The MRC London Neu-
rodegenerative Diseases Brain Bank at King’s College, London
(08/MRE09/38 + 5).
Samples of cortex of approximately 1 g frozen weight from tem-
poral, frontal, parietal and occipital lobes were obtained from 12
le under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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Fig. 1. Representative images of aluminium in frontal cortex. Light (A&D) and ﬂuorescence (B&E) microscopy images of lumogallion-stained sections of frontal cortex. Asterisk
label  suggested intracellular deposits while arrows show diffuse deposits. Fluorescence microscopy of un-stained adjacent tissue sections (C&F) show autoﬂuorescence. Scale
bars  are all 100 m.
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aig. 2. Representative images of aluminium in parietal cortex. Light (A&D) and ﬂuore
abel  suggested intracellular deposits associated with both living and dead cells. Fluo
cale  bars are 100 m (A–C) and 50 m (D–F).
ases of autopsy-conﬁrmed familial Alzheimer’s disease. Donors
ith familial Alzheimer’s disease are extremely rare and we had
he privilege of obtaining tissue from the only 12 cases available
t the brain bank with the year of diagnosis ranging from 1991
hrough to 2009. There were 7 female and 5 male donors in the age
ange 42–86. The bases for a diagnosis of familial Alzheimer’s dis-
ase are given in Table 1. Where no deﬁnite genetic mutation was
ecorded at the time of autopsy we have deﬁned probable famil-
al Alzheimer’s disease as either (i) having two ﬁrst degree relatives
ith a dementing illness or (ii) where the patient or ﬁrst degree rel-
tive had developed symptoms of dementia at less than 60 years of
ge or (iii) where the patient had one ﬁrst and one second degree (B&E) microscopy images of lumogallion-stained sections of frontal cortex. Asterisk
ce microscopy of un-stained adjacent tissue sections (C&F) show autoﬂuorescence.
relative with dementia and one with symptoms of dementia at less
than 60 years of age.
The aluminium content of these tissues was  measured by
an established and fully validated method [8] which herein is
described brieﬂy. Thawed tissues were cut using a stainless steel
blade to give individual samples of ca 0.3 g (3 sample replicates
for each lobe) wet weight and dried to a constant weight at 37 ◦C.
Dried and weighed tissues were digested in a microwave (MARS
Xpress CEM Microwave Technology Ltd.) in a mixture of 1 mL
15.8 M HNO3 (Fisher Analytical Grade) and 1 mL 30% w/v H2O2 (BDH
Aristar). Digests were clear with no fatty residues and, upon cool-
ing, were made up to 5 mL  volume using ultrapure water (cond
<0.067 S/cm). Total aluminium was measured in each sample
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Fig. 3. Representative images of aluminium in cortex. Light (A&D) and ﬂuorescence (B&E) microscopy images of lumogallion-stained sections of frontal (A&B) and temporal
(D&E)  cortex. Asterisk label suggested intracellular deposits and arrows diffuse deposits. Fluorescence microscopy of un-stained adjacent frontal (C) and temporal (F) tissue
sections  show autoﬂuorescence. Scale bars are 50 m (A–C) and 100 m (D–F).
Fig. 4. Co-localisation of amyloid and aluminium in occipital cortex. (A) Light microscopy image of Congo red-stained tissue showing (arrow) senile plaque-like amyloid
d rrow) 
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luorescence microscopy image of Congo red-stained tissue showing (arrow) senil
issue  stained with lumogallion and showing (arrow) signiﬁcant deposits of alumin
y transversely-heated graphite furnace atomic absorption spec-
rometry (TH GFAAS) using matrix-matched standards and an
stablished analytical programme [8].
Formalin-ﬁxed brain tissue for 6 cases of familial AD (A1, A5,
7, A8, A11 & A12) was supplied as pre-embedded parafﬁn blocks
epresenting cortical tissue from frontal, parietal, and temporal
nd occipital lobes. A recently developed, optimised and validated
ethod using lumogallion and ﬂuorescence microscopy was  usedapple-green birefringence characteristic of amyloid in  sheet conformation. (C)
ue-like amyloid deposit. (D) Fluorescence microscopy image of adjacent section of
cale bars are all 50 m.
to identify the presence of aluminium in tissues [16]. This method
was shown to be speciﬁc for aluminium with no interference
from any other metals and no issues relating to autoﬂuorescence.
Slides of serial adjacent sections of tissue were imaged using an
Olympus BX50 ﬂuorescence microscope with a BX-FLA reﬂected
light ﬂuorescence attachment, equipped with a mercury burner
and a vertical illuminator. For lumogallion (and autoﬂuorescence)
imaging a U-MNIB3 ﬂuorescence ﬁlter cube was used (bandpass
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xcitation ﬁlter: 470–495 nm,  dichromatic mirror: 505 nm,  long-
ass emission ﬁlter: 510 nm)  (both from Olympus, UK). Images
ere obtained using CellD software (Olympus Soft Imaging Solu-
ions GmbH).
. Results.1. Aluminium content of brain tissues
Aluminium was found in all 144 tissues and its concentration
anged from 0.01 to 35.65 g/g dry wt. (Table 1). The mean alu-
able 1
he content of aluminium in each of 4 lobes (O – occipital; F – frontal; T – temporal; P – pari
oncerning or pathologically-signiﬁcant are given in italics or bold typescript respectively.
PP  – amyloid precursor protein, BNE – Brain Net Europe.
Donor  ID  Pathology  and  genetics  Gender  
A1  Braak/BNE  stage  VI  M  
Grandfather, father,  brother  died  
with dementia,brother  had  a  
PSEN-1 mutation
A2 Braak  Stage  VI  F 
Father and  nephew  died  with  
dementia, nephew  developed  
dementia at  young  age  
A3 Braak  Stage  V-VI  M  
Father died  at  young  age  with  
AD 
A4 Braak  Stage  V-VI  M  
PSEN-1(DELTA4) 
A5 Braak  Stage  at  least  IV  M  
Mother and  brother  died  in  their  
50 s  with  dementia  
A6 Braak  stage  V-VI  F 
Daughter died  in 30  s  with
dementia edicine and Biology 40 (2017) 30–36 33
minium content for whole brains (n = 12) ranged from 0.34(0.26)
for individual A1 to 6.55(9.59) g/g dry wt. for individual A8.
Approximately 40% of tissues (57/144) had an aluminium con-
tent considered as pathologically-concerning (≥2.00 g/g dry wt.)
while approximately 58% of these tissues had an aluminium con-
tent considered as pathologically-signiﬁcant (≥3.00 g/g dry wt.).
The brains of 11 out of 12 individuals had at least one tissue with
a pathologically-signiﬁcant content of aluminium. The brains of
9 individuals had at least one tissue with an aluminium content
≥5.00 g/g dry wt. while 5 of these had at least one tissue with an
aluminium content ≥10.00 g/g dry wt.  (Table 1). The mean (SD)
etal) of 12 cases of familial Alzheimer’s disease. Values considered as pathologically-
 Details of pathology and known genetic mutations are also given. PSEN – presenilin,
Age  Lobe  Replicate  [Al]  g/g  dry  wt.
47 O 1 0.47
2 0.67
3 0.03
F  1 0.84
2 0.52
3  0.13
T 1 0.16
2 0.02
3 0.29
P 1 0.53
2 0.28
3 0.13
Mean(SD)  0.34(0.26)
76 O 1 10.12
2 8.32
3 11.54
F  1 1.75
2 4.48
3 0.48
T 1 0.69
2 0.55
3 0.16
P 1 0.27
2 1.25
3 1.60
Mean(SD)  3.43(4.17)
53 O 1 2.07
2 2.83
3 7.97
F  1 3.23
2 1.55
3 3.93
T 1 0.70
2 1.41
3 2.72
P 1 3.18
2 2.17
3 5.32
Mean(SD)  3.09(1.97)
42 O 1 0.10
2 4.79
3 0.52
F 1 3.11
2 0.85
3 1.48
T 1 0.48
2 2.37
3 2.51
P 1 8.40
2 1.11
3 0.39
Mean(SD)  2.18(2.39)
60  O 1 0.59
2 0.73
3 0.14
F  1 1.24
2 6.51
3 13.41
T 1 0.77
2 0.34
3 0.25
P 1 2.61
2 0.41
3 0.54
Mean(SD)  2.30(3.93)
86 O 1 25.80
2 0.66
3  2.25
F  1 3.91
2 9.89
3 1.61
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Table 1 (Continued)
Donor  ID  Pathology  and  genetics  Gender  Age  Lobe  Replicate  [Al]  g/g  dry  wt.
T 1  0.24
2 2.54
3 1.05
P 1  0.89
2 1.87
3 1.23
Mean(SD)  4.33(7.23)
A7 Braak/BNE  stage  VI,cotton  wool  F 69  O 1  1.22
plaques (PSEN  mutation)  and 2  1.62
limbic Lewy  bodies  3  0.97
dementia diagnosed  at  age  46  F 1  1.08
2 1.11
3 3.00
T 1  2.69
2 1.19
3 1.56
P 1  0.54
2 0.01
3 0.32
Mean(SD)  1.28(0.87)
A8 Braak  stage  VI  with  Lewy  bodies  F 65  O 1  2.44
2 1.73
PSEN-1 (E280G)  3  2.12
F 1  5.06
2 2.53
3 35.65
T 1  10.43
2 6.31
3 6.77
P 1  3.82
2 0.36
3 1.38
Mean(SD)  6.55(9.59)
A9 Braak  Stage  V–VI,  Lewy  bodies  F 72  O 1  2.53
2 2.93
APP717(VAL-ILE) 3  0.81
F 1  8.56
2 1.28
3 1.46
T 1  2.48
2 0.65
3 2.61
P 1  1.36
2 5.44
3 0.96
Mean(SD)  2.59(2.30)
A10 Braak  Stage  VI,  Lewy  bodies  F 49  O 1  2.38
2 4.14
PSEN-1 (L153V)  3  2.40
F 1  2.60
2 0.63
3 1.26
T 1  2.37
2 0.12
3 1.99
P 1  1.14
2 0.76
3 0.28
Mean(SD)  1.67(1.18)
A11 Braak  Stage  V-VI  F 69  O 1  23.93
2 0.85
APP717(VAL-ILE) 3  3.15
F 1  1.45
2 0.84
3 1.02
T 1  1.41
2 0.41
3 6.21
P 1  0.55
2 2.27
3 0.37
Mean(SD)  3.54  (6.63)
A12 Braak  at  least  Stage  IV  M  61  O 1  4.57
2 1.93
APP717(VAL-GLY) 3  0.85
F 1  1.81
2 2.54
3 0.84
T 1  6.00
2 0.27
3 2.47
a
3
tluminium content across all 12 individuals for each lobe were
.89(5.86), 3.66(6.18), 2.03(2.35) and 1.61(1.90) g/g dry wt.  for
he occipital, frontal, temporal and parietal lobes respectively. TheP 1  5.41
2 0.66
3 0.01
Mean(SD)  2.28(2.03)aluminium content of the parietal lobe was statistically different
to the occipital lobe (P = 0.029; df = 70) but there were no other
statistically signiﬁcant differences in lobe aluminium content.
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.2. Aluminium ﬂuorescence in brain tissues
Tissue sections from 6 of the 12 familial AD cases (A1, A5, A7,
8, A11 & A12) were investigated and the presence of aluminium
as conﬁrmed in each case using lumogallion and ﬂuorescence
icroscopy. Representative images of positive aluminium ﬂuo-
escence are shown in Figs. 1–3. Multiple deposits of aluminium
ere identiﬁed in each case and including in the brain of donor
1 which had the lowest mean aluminium content by TH GFAAS.
luminium was primarily identiﬁed in grey matter as clusters or
wathes of focal deposits some of which were densely stained and
–5 m in size while others were diffuse and up to 50 m in length
r diameter. Many of the former gave the impression of being
ntracellular being associated with astrocytes or neurons or tissue
paces vacated by dead or dying cells. The more diffuse deposits
ppeared to be extracellular and were similar in appearance to dif-
use deposits of A. Aggregates of lipofuscin were common in most
issues and some deposits of aluminium shared the appearance of
ccumulations of lipofuscin.
. Discussion
The aluminium content of brain tissue donated by individuals
ith a diagnosis of familial and probable familial Alzheimer’s dis-
ase was, overall, extremely high. The mean aluminium data for
ach lobe across all 12 donors are signiﬁcantly higher (P < 0.05 in
ach case) than equivalent data (using identical methods and qual-
ty assurance indices) for the same lobes from a previous study
hich included 60 human brains of which ca 60% had been diag-
osed as sporadic Alzheimer’s disease [8,12]. Herein we measured
ome of the highest values recorded for individual samples of
uman brain tissue, for example to highlight just a few, 11.54 g/g
n the occipital lobe of donor A2, 13.41 g/g in the frontal lobe of
5, 25.80 g/g in the occipital lobe of A6, 35.65 g/g in the frontal
obe of A8 and 23.93 g/g in the occipital lobe of A11 (Table 1).
hese individual values are higher than previous measurements
or non-AD and sporadic or late-onset AD brain tissue [7,8,12].
hile we have previously recorded values up to ca 13.00 g/g in
D with occupational exposure to aluminium [14] and one value
f 23.00 g/g in congophilic amyloid angiopathy (CAA) with envi-
onmental exposure to aluminium [13] the values measured herein
or familial AD are more similar to those which have been associ-
ted with aluminium-induced encephalopathies [17]. It was of note
hat while the aluminium content of brain tissue from donor A1
as consistently low across all 4 lobes (mean (SD) 0.34(0.26) g/g)
hen additional tissues from this donor were investigated by
uorescence microscopy signiﬁcant deposits of aluminium were
dentiﬁed across all 4 lobes. This observation tends to support the
revious contention of focal as opposed to homogeneous distribu-
ion of aluminium in human brain tissues [7,14].
The presence of aluminium in brain tissue from donors with
amilial AD was fully supported qualitatively by aluminium-
peciﬁc ﬂuorescence microscopy (Figs. 1–3). We  have produced
triking and unequivocal images of aluminium in human brain tis-
ue and conﬁrmed aluminium’s presence in each of the familial AD
rains investigated. Aluminium appeared to be both intracellular,
ssociated with dead and dying neurones and extracellular in large
iffuse deposits. Further detailed research will be required to con-
rm the precise locations of deposits of aluminium. Our images may
upport previous studies using various semi-quantitative tech-
iques which suggested the co-localisation of aluminium with;
eurones and neuroﬁbrillary tangles in AD [10] and dementia
ugilistica [18]; Lewy bodies in Parkinson’s disease [19]; lipofuscin
n AD [20] and senile plaques in AD [21]. We  have previously iden-
iﬁed the co-localisation of aluminium and amyloid in an AD brainedicine and Biology 40 (2017) 30–36 35
[7] and we  have additional evidence herein to support this (Fig. 4).
Aluminium is shown in the very near vicinity of a plaque-like struc-
ture which stained positively with Congo red and gave apple-green
birefringence under polarised light. However, emission spectra for
Congo red and lumogallion show signiﬁcant overlap and so addi-
tional research will be required to provide unequivocal evidence
by ﬂuorescence microscopy for the association of aluminium with
amyloid in diseased human brain tissue.
These data, supported by visual evidence of aluminium in brain
tissue, raise the possibility that genetic predisposition to AD is
accompanied by a higher propensity to accumulate and retain alu-
minium in the brain. In familial AD the expression and metabolism
of APP is altered and there is substantial evidence of a role for
A in disease aetiology [6]. The observation that A binds alu-
minium promoting its precipitation in a -sheet conformation
[22,23] alongside the known co-localisation of aluminium and A
in human brain tissue [7] might suggest a role for A in the reten-
tion and accumulation of aluminium in brain tissue in familial AD.
5. Conclusions
Aluminium is neurotoxic [11,23] and the concentrations of alu-
minium found in these familial AD brains are unlikely to be benign
and indeed are highly likely to have contributed to both the onset
and the aggressive nature of any ongoing AD in these individu-
als. These data lend support to the recent conclusion that brain
aluminium will contribute towards all forms of AD under certain
conditions [15].
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